Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
about
Current ebola vaccinesEbola virus vaccines: an overview of current approachesMouse models for filovirus infectionsVaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsDevelopment of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccinationEbola and Marburg virus vaccines.[Overview of the Ebola vaccines in pre-clinical and clinical development].Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeSubviral particle as vaccine and vaccine platform.Ebola Vaccine: How Far are we?A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virusLassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primatesA DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialEbola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicineHomologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.Advances in virus-like particle vaccines for filoviruses.Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.Filovirus vaccines.Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein.A thermostable, chromatographically purified Ebola nano-VLP vaccine.Progress in filovirus vaccine development: evaluating the potential for clinical use.Filovirus-like particles as vaccines and discovery tools.Generation and characterization of protective antibodies to Marburg virus.Forty-five years of Marburg virus research.Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine ImmunityDevelopment of vaccines for Marburg hemorrhagic fever.Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.Protection against filovirus infection: virus-like particle vaccines.Protection against lethal challenge by Ebola virus-like particles produced in insect cells.Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations
P2860
Q21534720-D6336DF1-19D3-46E8-AAD3-D96B1EFBA3D4Q26999232-D1EB4B55-4F5E-47AC-A414-04067D3959F9Q27011569-CF2E3D4E-FC37-4B71-8C83-E41700AD0E95Q27485491-5BA6C1D2-21D9-4879-8090-86828E694C2EQ30231394-7B1E5819-A41D-46BC-A03B-339BED76C14DQ30234637-1BB131D2-62EF-4B97-A528-DF9A527CB7ECQ30245207-A2A25006-C890-4567-A151-CD12A9C711DDQ30375784-EA437F16-408B-402B-BB70-5CCBBF2DAC0FQ31152190-D15D83AE-C7F2-4631-8A2A-6C2C389F7421Q33558475-426F9189-94F7-4362-9F5D-9130310A2E8CQ33621078-F1ABE20C-A4D6-4239-8A4C-DE1B7C5F691BQ33812653-33B239C1-4151-49F5-9C76-5B8B165B5378Q33831877-B9045D0C-AECA-4DEA-AEF6-656048FD4E43Q34000122-8A795DFB-983A-45FA-B6F7-8BD1B9133BAFQ34322342-6D63B850-1B60-489F-A82E-6AB1E2A2CBE1Q34468847-54B6D9FA-AF55-41DE-B872-B693E021A648Q34571072-2F3A618E-EA92-42C4-B9A7-642A085C8377Q34583832-73D3AD80-C925-4E75-AA4F-3B074A84C0B8Q34632946-1C494B2A-E877-4880-82E8-49BB6A161083Q34774783-651DEBE3-05C9-41C5-84F7-92AEE1F0B88FQ35048254-D9E813AB-DBB2-4BD7-9056-D002E708392AQ35202880-545C6438-87A3-4AC2-B224-9F83BE4FA6B0Q35300029-04F92F62-B859-400A-8823-53CA2444B631Q35300062-A3390C9D-3CD0-4E49-BC3A-7A8E8F94CC74Q35558539-461C6CC4-A45D-4410-82CB-7BC64A73D42DQ35608833-DCAD0F6D-934C-4FE5-8273-E0BDBF2200DAQ35853669-BFA43A16-5006-46A3-869F-562C8DD58B92Q36100545-EC8236A4-FED9-4FD5-B964-196A441BD82DQ36198685-3D10B65E-9BF4-4B53-9EB4-E623ABF6BB39Q36305916-3BD34766-2230-412C-8133-37D42E8BA148Q36395831-025B4E1F-F294-409B-8932-FE3C99C0A8F6Q36433538-EC3CA5FD-3A2D-484A-922A-C13B9EA9DED0Q36538834-BCA0BFEA-A1F2-496B-9B03-B8BDC25CCA34Q36728793-62BE472C-3E53-4C1E-9E08-EE5DA8967E54Q36759754-9DF93A9C-C579-434E-9AE1-B2D2A263291EQ36845999-DDD7000E-FAC2-47DF-B94E-4913C7CBBC94Q36995725-C3715AA1-730A-471D-957E-2B65088C504CQ37130463-2CB6F024-9B45-4C3D-919C-B65455806DB9Q37131622-180F539F-7230-49F1-8DB6-799CF5807B1FQ37232054-112DCD3F-EEB2-4058-9C1C-3E144B18BE58
P2860
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Virus-like particles exhibit p ...... and Marburg viral infections.
@en
type
label
Virus-like particles exhibit p ...... and Marburg viral infections.
@en
prefLabel
Virus-like particles exhibit p ...... and Marburg viral infections.
@en
P2093
P921
P1433
P1476
Virus-like particles exhibit p ...... and Marburg viral infections.
@en
P2093
Alan Schmaljohn
Dana L Swenson
Diane L Negley
Kelly L Warfield
M Javad Aman
P304
P356
10.1016/J.VACCINE.2004.11.070
P407
P50
P577
2005-04-01T00:00:00Z